Drug news
FDA Advisory Committee recommends Tresiba and Ryzodeg for Types 1 and 2 Diabetes
The FDA's Endocrinologic and Metabolic Drugs Advisory Committee has unanimously recommended that a cardiovascular outcomes trial should be conducted regarding the New Drug Applications (NDA) for Tresiba (insulin degludec )and Ryzodeg (insulin degludec/insulin aspart), and voted 8-4 in favor of approving the products with a post-approval outcomes trial commitment
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins